Beam Therapeutics Inc (BEAM) Stock Price, Quote & News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304,...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 327 8775

Website: beamtx.com

Address:

238 Main Street, Cambridge, United States

vjtweet May. 8 at 6:55 PM

$BEAM on breakout watch..

0 · Reply

NewEarth May. 8 at 2:34 PM

$NTLA $BEAM $EDIT $REGN $PRME Jennifer and Intellia are going to hold the market of all these treatments

0 · Reply

MorganHoratio May. 8 at 1:24 PM

Google just released its updated 13F filing which shows all the stocks it owned as of the end of Q1: $ARM - 1,960,784 shares $ASTS - 8,943,486 $AUTL - 698,262 $BEAM - 321,604 $BBIO - 2,823,126 Google's Q1 13F is a masterclass in Space, Silicon, and AI Bio! The standout is definitely the 8.9M share stake in $ASTS. Despite the looming SpaceX IPO, Google is doubling down on this "Space-based Cell Tower"—a clear play for global Gemini AI dominance. $ARM remains the bedrock of its custom silicon (Axion) strategy, while $BEAM and $BBIO highlight a massive pivot into AI-driven drug discovery. Do you think $ASTS is Google's ultimate strategic hedge against Starlink in 2026? Which of these deep-tech plays are you adding to your watchlist?

1 · Reply

RocroBio May. 7 at 5:40 PM

$BEAM $CRBU $EDIT $NTLA

0 · Reply

BarneyR May. 7 at 4:17 PM

$BEAM In the most recent quarter (Q1), Beam Therapeutics reported EPS of $-0.91, beating estimates of $-0.98 by 0.07%. Revenue came in at $31.74M, exceeding the estimate of $13.94M by 1.28%. Beam Therapeutics has beaten EPS estimates in 2 consecutive quarters. Over the last 4 quarters, Beam Therapeutics has averaged an EPS surprise of 0.28% and a revenue surprise of 2.31%.

0 · Reply

BarneyR May. 7 at 4:12 PM

$BEAM Q1 '26 report. Beat estimates on expected loss and beat estimates on expected revenues.

0 · Reply

alvicryptz May. 7 at 2:27 PM

$BEAM very important price for BEAM before earnings. Near resistance and might be manipulated here. Bad news and profits will be taken here, good news and resistance will be broken. My experience says that when price goes up before earnings, bad things might happen. I'm in, haven't sold. Lets see what will happen here.

0 · Reply